Prognostic value of cardiac magnetic resonance early after ST-segment elevation myocardial infarction in older patients.


Journal

Age and ageing
ISSN: 1468-2834
Titre abrégé: Age Ageing
Pays: England
ID NLM: 0375655

Informations de publication

Date de publication:
02 11 2022
Historique:
received: 29 03 2022
revised: 05 08 2022
entrez: 27 11 2022
pubmed: 28 11 2022
medline: 30 11 2022
Statut: ppublish

Résumé

older patients with ST-segment elevation myocardial infarction (STEMI) represent a very high-risk population. Data on the prognostic value of cardiac magnetic resonance (CMR) in this scenario are scarce. the registry comprised 247 STEMI patients over 70 years of age treated with percutaneous intervention and included in a multicenter registry. Baseline characteristics, echocardiographic parameters and CMR-derived left ventricular ejection fraction (LVEF, %), infarct size (% of left ventricular mass) and microvascular obstruction (MVO, number of segments) were prospectively collected. The additional prognostic power of CMR was assessed using adjusted C-statistic, net reclassification index (NRI) and integrated discrimination improvement index (IDI). during a 4.8-year mean follow-up, the number of first major adverse cardiac events (MACE) was 66 (26.7%): 27 all-cause deaths and 39 re-admissions for acute heart failure. Predictors of MACE were GRACE score (HR 1.03 [1.02-1.04], P < 0.001), CMR-LVEF (HR 0.97 [0.95-0.99] per percent increase, P = 0.006) and MVO (HR 1.24 [1.09-1.4] per segment, P = 0.001). Adding CMR data significantly improved MACE prediction compared to the model with baseline and echocardiographic characteristics (C-statistic 0.759 [0.694-0.824] vs. 0.685 [0.613-0.756], NRI = 0.6, IDI = 0.08, P < 0.001). The best cut-offs for independent variables were GRACE score > 155, LVEF < 40% and MVO ≥ 2 segments. A simple score (0, 1, 2, 3) based on the number of altered factors accurately predicted the MACE per 100 person-years: 0.78, 5.53, 11.51 and 78.79, respectively (P < 0.001). CMR data contribute valuable prognostic information in older patients submitted to undergo CMR soon after STEMI. The Older-STEMI-CMR score should be externally validated.

Sections du résumé

BACKGROUND
older patients with ST-segment elevation myocardial infarction (STEMI) represent a very high-risk population. Data on the prognostic value of cardiac magnetic resonance (CMR) in this scenario are scarce.
METHODS
the registry comprised 247 STEMI patients over 70 years of age treated with percutaneous intervention and included in a multicenter registry. Baseline characteristics, echocardiographic parameters and CMR-derived left ventricular ejection fraction (LVEF, %), infarct size (% of left ventricular mass) and microvascular obstruction (MVO, number of segments) were prospectively collected. The additional prognostic power of CMR was assessed using adjusted C-statistic, net reclassification index (NRI) and integrated discrimination improvement index (IDI).
RESULTS
during a 4.8-year mean follow-up, the number of first major adverse cardiac events (MACE) was 66 (26.7%): 27 all-cause deaths and 39 re-admissions for acute heart failure. Predictors of MACE were GRACE score (HR 1.03 [1.02-1.04], P < 0.001), CMR-LVEF (HR 0.97 [0.95-0.99] per percent increase, P = 0.006) and MVO (HR 1.24 [1.09-1.4] per segment, P = 0.001). Adding CMR data significantly improved MACE prediction compared to the model with baseline and echocardiographic characteristics (C-statistic 0.759 [0.694-0.824] vs. 0.685 [0.613-0.756], NRI = 0.6, IDI = 0.08, P < 0.001). The best cut-offs for independent variables were GRACE score > 155, LVEF < 40% and MVO ≥ 2 segments. A simple score (0, 1, 2, 3) based on the number of altered factors accurately predicted the MACE per 100 person-years: 0.78, 5.53, 11.51 and 78.79, respectively (P < 0.001).
CONCLUSIONS
CMR data contribute valuable prognostic information in older patients submitted to undergo CMR soon after STEMI. The Older-STEMI-CMR score should be externally validated.

Identifiants

pubmed: 36436010
pii: 6847804
doi: 10.1093/ageing/afac248
pii:
doi:

Types de publication

Multicenter Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© The Author(s) 2022. Published by Oxford University Press on behalf of the British Geriatrics Society. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Auteurs

Ana Gabaldón-Pérez (A)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.
Health Research Institute - INCLIVA, Valencia, 46010, Spain.

Víctor Marcos-Garcés (V)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.
Health Research Institute - INCLIVA, Valencia, 46010, Spain.

José Gavara (J)

Health Research Institute - INCLIVA, Valencia, 46010, Spain.
Center for Biomaterials and Tissue Engineering, Universitat Politècnica de València, Valencia, 46022, Spain.

María P López-Lereu (MP)

Cardiovascular Magnetic Resonance Unit, ASCIRES Biomedical Group, Valencia, 46004, Spain.

José V Monmeneu (JV)

Cardiovascular Magnetic Resonance Unit, ASCIRES Biomedical Group, Valencia, 46004, Spain.

Nerea Pérez (N)

Health Research Institute - INCLIVA, Valencia, 46010, Spain.

César Ríos-Navarro (C)

Health Research Institute - INCLIVA, Valencia, 46010, Spain.

Elena de Dios (E)

Faculty of Medicine and Odontology, University of Valencia, Valencia, 46010, Spain.

Héctor Merenciano-González (H)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.
Health Research Institute - INCLIVA, Valencia, 46010, Spain.

Joaquim Cànoves (J)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.

Paolo Racugno (P)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.

Clara Bonanad (C)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.
Health Research Institute - INCLIVA, Valencia, 46010, Spain.
Faculty of Medicine and Odontology, University of Valencia, Valencia, 46010, Spain.

Gema Minana (G)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.
Health Research Institute - INCLIVA, Valencia, 46010, Spain.
Faculty of Medicine and Odontology, University of Valencia, Valencia, 46010, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, 28029, Spain.

Julio Núnez (J)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.
Health Research Institute - INCLIVA, Valencia, 46010, Spain.
Faculty of Medicine and Odontology, University of Valencia, Valencia, 46010, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, 28029, Spain.

David Moratal (D)

Center for Biomaterials and Tissue Engineering, Universitat Politècnica de València, Valencia, 46022, Spain.

Francisco J Chorro (FJ)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.
Health Research Institute - INCLIVA, Valencia, 46010, Spain.
Faculty of Medicine and Odontology, University of Valencia, Valencia, 46010, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, 28029, Spain.

Filipa Valente (F)

Hospital Universitari Vall d'Hebron, Department of Cardiology, Barcelona, 08035, Spain.

Daniel Lorenzatti (D)

Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, 08036, Spain.

Jose T Ortiz-Pérez (JT)

Institut d'Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Barcelona, 08036, Spain.
Cardiovascular Institute, Hospital Clínic, Barcelona, 08036, Spain.

Jose F Rodríguez-Palomares (JF)

Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, 28029, Spain.
Hospital Universitari Vall d'Hebron, Department of Cardiology, Barcelona, 08035, Spain.
Vall d'Hebron Institut de Recerca (VHIR), Barcelona, 08035, Spain.
Universitat Autònoma de Barcelona, Barcelona, 08193, Spain.

Vicente Bodí (V)

Department of Cardiology, Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain.
Health Research Institute - INCLIVA, Valencia, 46010, Spain.
Faculty of Medicine and Odontology, University of Valencia, Valencia, 46010, Spain.
Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBER-CV), Madrid, 28029, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH